Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Drug Manufacturers — Specialty and Generic

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company offers pharmaceuticals for the treatment of breast cancer, hypertension, ventricular arrhythmias, stage D2 metastatic carcinoma of the prostate, depression, diarrhea, infections, vasomotor symptoms of menopause, pain caused by osteoarthritis and rheumatoid arthritis, epilepsy, arrhythmia, obsessive-compulsive disorder and social anxiety disorder, ulcerative colitis, salt and fluid retention, manic episodes of bipolar disorder, ulcerative colitis, proctosigmoiditis, ocular conditions, metastatic prostate cancer, arrhythmia, migraine headache, and enterocolitis caused by staphylococcus aureus. It also provides aspirin and extended-release dipyridamole; Cholestyramine, an adjunctive therapy to diet for the reduction of elevated serum cholesterol; Ezetimibe-Simvastatin to lower high cholesterol and triglyceride levels; Fenofibrate, a peroxisome proliferator receptor alpha activator; Hydrocortisone rectal cream for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Morphine Sulfate, an oral solution for acute and chronic pain mana...
Website: anipharmaceuticals.com



Growth: Good revenue growth rate 40.4%, there is acceleration compared to average historical growth rates 37.6%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is positive, +21.9%. On average the margin is improving unsteadily. Gross margin is high, +47.9%. In the last quarter the company beat the estimated EPS, +234.3%. The company was ahead of estimated EPS in 60% of quarters (showing a gain of +$0.14 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 13.6% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 191.3% higher than minimum and 3.5% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 4.5x by EV / Sales multiple , the company can be 61.9% undervalued

Insiders: For the last 3 months insiders sold company shares on $15.2 mln (-1.211% of cap.)

Key Financials (Download financials)

Ticker: ANIP
Share price, USD:  (0.0%)67.25
year average price 57.15  


year start price 42.58 2023-05-08

min close price 40.88 2023-05-15

max close price 69.69 2024-03-27

current price 67.25 2024-05-06
Common stocks: 19 003 000

Dividend Yield:  0.0%
FCF Yield LTM: 13.6%
EV / LTM EBITDA: 12.8x
EV / EBITDA annualized: 15.5x
Last revenue growth (y/y):  40.4%
Last growth of EBITDA (y/y):  > 200.0%
Historical revenue growth:  37.6%
Historical growth of EBITDA:  66.5%
EV / Sales: 2.8x
Margin (EBITDA LTM / Revenue): 21.9%
Fundamental value created in LTM:
Market Cap ($m): 1 278
Net Debt ($m): 89
EV (Enterprise Value): 1 367
Price to Book: 3.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-05-03Zacks Investment Research

ANI Pharmaceuticals (ANIP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

2024-04-18GlobeNewsWire

ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET

2024-04-15Zacks Investment Research

Why ANI (ANIP) is Poised to Beat Earnings Estimates Again

2024-04-05Zacks Investment Research

Wall Street Analysts Think ANI (ANIP) Is a Good Investment: Is It?

2024-03-27Zacks Investment Research

ANI Pharmaceuticals (ANIP) Rises Yet Lags Behind Market: Some Facts Worth Knowing

2024-03-26Zacks Investment Research

ANI Pharmaceuticals, Inc. (ANIP) Hits Fresh High: Is There Still Room to Run?

2024-03-14Zacks Investment Research

Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?

2024-03-12Seeking Alpha

Top 10 Small-Cap Stocks (SA Quant)

2024-03-06Zacks Investment Research

What Makes ANI Pharmaceuticals (ANIP) a Strong Momentum Stock: Buy Now?

2024-03-01Zacks Investment Research

Wall Street Analysts See ANI (ANIP) as a Buy: Should You Invest?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ANIP ANIP ANIP ANIP ANIP ANIP
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-02-29 2023-11-08 2023-08-09 2023-05-08 2023-03-09 2022-11-09
acceptedDate 2024-02-29 07:22:42 2023-11-08 07:01:33 2023-08-09 07:00:53 2023-05-08 08:33:08 2023-03-09 16:09:01 2022-11-09 08:02:00
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 132M 132M 117M 107M 94M 84M
costOfRevenue 69M 48M 42M 38M 36M 33M
grossProfit 63M 84M 74M 69M 58M 51M
grossProfitRatio 0.479 0.635 0.637 0.647 0.615 0.608
researchAndDevelopmentExpenses 10M 11M 7M 6M 5M 8M
generalAndAdministrativeExpenses 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 44M 42M 39M 36M 33M 30M
otherExpenses -33 000 -39 000 -53 000 15M 14M 14M
operatingExpenses 54M 68M 61M 57M 53M 52M
costAndExpenses 123M 116M 103M 95M 89M 85M
interestIncome 0 6M 7M 0 0 0
interestExpense 6M 6M 7M 8M 8M 7M
depreciationAndAmortization 15M 15M 15M 17M 14M 15M
ebitda 24M 31M 28M 27M 19M 14M
ebitdaratio 0.182 0.232 0.241 0.250 0.206 0.172
operatingIncome 9M 18M 12M 10M 5M -941 000
operatingIncomeRatio 0.066 0.136 0.106 0.093 0.053 -0.011
totalOtherIncomeExpensesNet -8M 3M -1M -8M -11M -11M
incomeBeforeTax 947 000 12M 5M 2M -6M -12M
incomeBeforeTaxRatio 0.007 0.087 0.045 0.020 -0.061 -0.146
incomeTaxExpense -208 000 2M -996 000 726 000 -1M -4M
netIncome 1M 10M 6M 1M -4M -9M
netIncomeRatio 0.009 0.075 0.054 0.013 -0.045 -0.103
eps 0.039 0.500 0.300 0.060 -0.260 -0.530
epsdiluted 0.039 0.500 0.290 0.060 -0.260 -0.530
weightedAverageShsOut 19M 19M 18M 16M 16M 16M
weightedAverageShsOutDil 19M 19M 18M 17M 16M 16M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ANIP ANIP ANIP ANIP ANIP ANIP
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-02-29 2023-11-08 2023-08-09 2023-05-08 2023-03-09 2022-11-09
acceptedDate 2024-02-29 07:22:42 2023-11-08 07:01:33 2023-08-09 07:00:53 2023-05-08 08:33:08 2023-03-09 16:09:01 2022-11-09 08:02:00
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 221M 193M 162M 68M 48M 56M
shortTermInvestments 0 0 0 0 0 0
cashAndShortTermInvestments 221M 193M 162M 68M 48M 56M
netReceivables 162M 179M 173M 175M 165M 140M
inventory 111M 107M 104M 104M 105M 96M
otherCurrentAssets 25M 11M 8M 7M 8M 17M
totalCurrentAssets 520M 497M 459M 365M 344M 309M
propertyPlantEquipmentNet 45M 44M 44M 43M 43M 43M
goodwill 28M 28M 28M 28M 28M 28M
intangibleAssets 209M 220M 230M 239M 252M 264M
goodwillAndIntangibleAssets 237M 248M 259M 267M 280M 292M
longTermInvestments 6M 10M 9M 0 0 0
taxAssets 91M 84M 82M 81M 81M 77M
otherNonCurrentAssets 6M 6M 6M 9M 11M 17M
totalNonCurrentAssets 385M 393M 400M 400M 416M 430M
otherAssets 0 0 0 0 0 0
totalAssets 904M 890M 859M 765M 760M 739M
accountPayables 37M 34M 29M 33M 29M 19M
shortTermDebt 850 000 850 000 850 000 850 000 850 000 850 000
taxPayables 8M 594 000 4M 4M 4M 4M
deferredRevenue 8M 75M 4M 0 0 0
otherCurrentLiabilities 100M 24M 89M 92M 69M 62M
totalCurrentLiabilities 145M 134M 123M 126M 99M 82M
longTermDebt 310M 285M 285M 285M 286M 286M
deferredRevenueNonCurrent 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 81M 77M
otherNonCurrentLiabilities 17M 16M 17M 14M -45M 301M
totalNonCurrentLiabilities 326M 301M 302M 300M 322M 321M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 5M 5M 0 0 0 0
totalLiabilities 472M 435M 425M 426M 422M 402M
preferredStock 25M 25M 25M 25M 25M 25M
commonStock 2000.000 2000.000 2000.000 1000.000 1000.000 1000.000
retainedEarnings -80M -81M -90M -96M -97M -93M
accumulatedOtherComprehensiveIncomeLoss 9M 14M 14M 11M 12M 10M
othertotalStockholdersEquity 479M 497M 486M 400M 399M 394M
totalStockholdersEquity 433M 455M 434M 339M 339M 337M
totalEquity 433M 455M 434M 339M 339M 337M
totalLiabilitiesAndStockholdersEquity 904M 890M 859M 765M 760M 739M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 904M 890M 859M 765M 760M 739M
totalInvestments 6M 10M 9M 0 0 0
totalDebt 315M 286M 286M 286M 287M 287M
netDebt 94M 93M 124M 219M 238M 230M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ANIP ANIP ANIP ANIP ANIP ANIP
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-02-29 2023-11-08 2023-08-09 2023-05-08 2023-03-09 2022-11-09
acceptedDate 2024-02-29 07:22:42 2023-11-08 07:01:33 2023-08-09 07:00:53 2023-05-08 08:33:08 2023-03-09 16:09:01 2022-11-09 08:02:00
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
netIncome 1M 10M 6M 1M -4M -9M
depreciationAndAmortization 15M 15M 15M 15M 16M 15M
deferredIncomeTax -8M -3M -910 000 773 000 -2M -2M
stockBasedCompensation 6M 5M 5M 4M 4M 4M
changeInWorkingCapital 28M 6M -7M -2M -21M -9M
accountsReceivables 17M -6M 2M -9M -25M 10M
inventory -5M -2M -669 000 2M -9M -3M
accountsPayables 3M 6M -4M 3M 10M -9M
otherWorkingCapital 13M 8M -4M 3M 4M -7M
otherNonCashItems 3M -731 000 2M 2M 3M 5M
netCashProvidedByOperatingActivities 45M 32M 21M 21M -4M 4M
investmentsInPropertyPlantAndEquipment -5M -5M -7M -2M -3M -10M
acquisitionsNet 0 0 0 0 0 -33 000
purchasesOfInvestments 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0
otherInvestingActivites -3M -3M 0 0 0 33 000
netCashUsedForInvestingActivites -5M -5M -7M -2M -3M -10M
debtRepayment -750 000 -750 000 -750 000 -750 000 -750 000 -750 000
commonStockIssued 2M 6M 82M 0 0 0
commonStockRepurchased -231 000 -670 000 -537 000 -4M -119 000 -239 000
dividendsPaid -406 000 -406 000 -407 000 -406 000 -407 000 -406 000
otherFinancingActivites -13M 4M 0 157 000 768 000 484 000
netCashUsedProvidedByFinancingActivities -12M 4M 80M -5M -508 000 -911 000
effectOfForexChangesOnCash -6M 0 -80M 0 0 0
netChangeInCash 28M 31M 94M 15M -8M -7M
cashAtEndOfPeriod 221M 193M 162M 68M 53M 61M
cashAtBeginningOfPeriod 193M 162M 68M 53M 61M 68M
operatingCashFlow 45M 32M 21M 21M -4M 4M
capitalExpenditure -5M -5M -7M -2M -3M -10M
freeCashFlow 40M 28M 14M 19M -8M -6M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q4
2024-02-29 ET (fiscal 2023 q4)
2023 q3
2023-11-08 ET (fiscal 2023 q3)
2023 q2
2023-08-09 ET (fiscal 2023 q2)
2023 q1
2023-05-08 ET (fiscal 2023 q1)
2022 q4
2023-03-09 ET (fiscal 2022 q4)
2022 q3
2022-11-09 ET (fiscal 2022 q3)
2022 q2
2022-08-08 ET (fiscal 2022 q2)
2022 q1
2022-05-10 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-02-29 11:50 ET
ANI Pharmaceuticals Reports Fourth Quarter and Record Full-Year 2023 Financial Results and Provides 2024 Guidance
2024-02-20 11:50 ET
ANI Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference
2024-02-07 11:50 ET
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024, at 8:30 a.m. ET
2024-01-29 11:50 ET
ANI Pharmaceuticals to Participate at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
2024-01-23 11:50 ET
ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP
2024-01-16 11:50 ET
ANI Pharmaceuticals Announces the FDA Approval and Launch of Indomethacin Oral Suspension, USP
2023-11-22 14:26 ET
ANI Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference
2023-11-08 11:50 ET
ANI Pharmaceuticals Reports Record Third Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance
2023-10-30 10:50 ET
ANI Pharmaceuticals to Participate at Two Upcoming Healthcare Conferences
2023-10-25 10:50 ET
ANI Pharmaceuticals to Discuss Third Quarter 2023 Financial Results on November 8, 2023, at 8:30 a.m. ET
2023-10-02 10:50 ET
ANI Pharmaceuticals Announces FDA Approval and Commercial Availability of New 1-mL Vial Size of Purified Cortrophin® Gel, Appropriate for Adjunctive Treatment of Certain Patients with Acute Gouty Arthritis Flares
2023-09-18 20:05 ET
ANI Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2023
2023-09-12 10:50 ET
ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Tablets USP
2023-08-28 10:50 ET
ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.1%
2023-08-24 10:50 ET
ANI Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
2023-08-23 10:50 ET
ANI Pharmaceuticals Appoints Healthcare Executive Matthew J. Leonard to its Board of Directors
2023-08-09 10:50 ET
ANI Pharmaceuticals Reports Record Second Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance  
2023-07-31 11:17 ET
ANI Pharmaceuticals to Discuss Second Quarter 2023 Financial Results on August 9, 2023, at 8:30 a.m. ET
2023-05-22 20:05 ET
ANI Pharmaceuticals to Present at the Jefferies Healthcare Conference
2023-05-16 20:05 ET
ANI Pharmaceuticals Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
2023-05-15 10:50 ET
ANI Pharmaceuticals Announces FDA Approval and Commercialization of Two ANDAs with CGT Exclusivity
2023-05-12 11:03 ET
ANI Pharmaceuticals Announces Pricing of $75 Million Public Offering of Common Stock
2023-05-11 20:01 ET
ANI Pharmaceuticals Announces Proposed Public Offering of Common Stock
2023-05-08 10:50 ET
ANI Pharmaceuticals Reports Record First Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance
2023-04-27 10:50 ET
ANI Pharmaceuticals to Discuss First Quarter 2023 Financial Results on May 8, 2023, at 8:30 a.m. ET
2023-04-26 20:15 ET
ANI Pharmaceuticals to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
2023-04-24 10:50 ET
ANI Pharmaceuticals Announces the FDA Approval and Launch of Nitrofurantoin Oral Suspension USP
2023-04-04 10:50 ET
ANI Pharmaceuticals Announces the FDA Approval of Colestipol Hydrochloride Tablets USP
2023-03-09 11:50 ET
ANI Pharmaceuticals Reports Record Fourth Quarter Financial Results and Achieves Full Year 2022 Revenue Milestone; Initiates 2023 Guidance
2023-03-02 12:00 ET
Cosette Pharmaceuticals Launches Betaine Anhydrous Powder, AB-rated to Cystadane® (betaine anhydrous for oral solution)
2023-02-22 21:05 ET
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023, at 8:30 a.m. ET
2022-12-19 21:56 ET
ANI Pharmaceuticals Announces the FDA Approval and Launch of Levocarnitine Tablets USP
2022-11-28 11:50 ET
ANI Pharmaceuticals Announces the FDA Approval and Launch of Fluoxetine Oral Solution USP
2022-11-16 11:50 ET
ANI Pharmaceuticals Announces the FDA Approval and Launch of Trimethoprim Tablets USP
2022-11-09 11:50 ET
ANI Pharmaceuticals Reports Third Quarter 2022 Financial Results; Reports Record Net Revenues
2022-10-24 10:50 ET
ANI Pharmaceuticals to Discuss Third Quarter 2022 Financial Results on November 9, 2022, at 8:00 a.m. ET
2022-09-12 10:50 ET
ANI Pharmaceuticals Appoints Krista Davis as Chief Human Resources Officer
2022-08-30 20:05 ET
ANI Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
2022-08-29 10:50 ET
ANI Pharmaceuticals Announces the Launch of Prochlorperazine Maleate Tablets USP
2022-08-16 10:50 ET
ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Dexamethasone Tablets USP
2022-08-08 10:50 ET
ANI Pharmaceuticals Reports Second Quarter 2022 Financial Results; Reports Record Net Revenues and Raises Full-Year 2022 Net Revenue Guidance for Purified Cortrophin® Gel
2022-08-03 10:50 ET
ANI Pharmaceuticals Announces the Launch of Acebutolol Hydrochloride Capsules USP
2022-07-28 10:50 ET
ANI Pharmaceuticals Acquires ANDAs from Oakrum Pharma, LLC
2022-07-25 20:05 ET
ANI Pharmaceuticals to Discuss Second Quarter 2022 Financial Results on August 8, 2022, at 8:00 a.m. ET
2022-07-18 10:50 ET
ANI Pharmaceuticals Appoints Meredith W. Cook as SVP, General Counsel and Corporate Secretary
2022-06-22 10:50 ET
ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Clorazepate Dipotassium Tablets USP
2022-06-21 11:03 ET
ANI Pharmaceuticals Adopts Veeva Commercial Cloud to Better Support Rare Disease Patients
2022-06-02 20:05 ET
ANI Pharmaceuticals Announces Consolidation of Manufacturing Network, Capturing Operational Synergies Post Novitium Acquisition
2022-06-01 20:15 ET
ANI Pharmaceuticals Announces the FDA Approval and Imminent Launch of Fludrocortisone Acetate Tablets USP
2022-05-20 10:50 ET
ANI Pharmaceuticals to Present at Upcoming Healthcare Investor Conferences
2022-05-10 10:50 ET
ANI Pharmaceuticals Reports First Quarter 2022 Results; Provides Purified Cortrophin® Gel Net Revenue Guidance and Full-Year 2022 Total Company Net Revenue Guidance of $295 Million to $315 Million
2022-04-19 10:50 ET
ANI Pharmaceuticals to Discuss First Quarter 2022 Financial Results on May 10, 2022
2022-04-11 10:50 ET
ANI Pharmaceuticals Announces the Launch of Misoprostol Tablets
2022-03-22 20:05 ET
ANI Pharmaceuticals Appoints Experienced Commercial Leader, Renee P. Tannenbaum, Pharm.D., MBA, to Board of Directors
2022-03-15 10:50 ET
ANI Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; Strong Foundation in Place to Drive Sustainable Growth
2022-03-07 11:50 ET
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022
2022-02-24 11:50 ET
ANI Pharmaceuticals Strengthens Rare Disease Business Unit Leadership Team
2022-02-14 22:00 ET
Oakrum Pharma and ANI Pharmaceuticals Announce the Launch of Betaine Anhydrous Powder, the first Generic Version of Cystadane® (betaine anhydrous for oral solution) Powder, Including 180 Days of Exclusivity
2022-01-24 11:50 ET
ANI Pharmaceuticals Announces Commercial Availability of Purified Cortrophin™ Gel (Repository Corticotropin Injection USP) for Multiple Chronic Autoimmune Disorders
2022-01-03 21:30 ET
ANI Pharmaceuticals to Present at the H.C. Wainwright Bioconnect Virtual Conference
2021-12-21 11:50 ET
ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Rifabutin Capsules USP
2021-11-22 11:50 ET
ANI Pharmaceuticals Completes Acquisition of Novitium Pharma, Significantly Enhancing R&D Capabilities and Scale of Generics and CDMO Businesses
2021-11-22 11:40 ET
ANI Pharmaceuticals to Present at the Piper Sandler 33rd Annual Healthcare Conference 2021
2021-11-11 11:50 ET
ANI Pharmaceuticals Receives Clearance from U.S. Federal Trade Commission for the Acquisition of Novitium Pharma
2021-11-08 21:05 ET
ANI Pharmaceuticals, Inc. Announces Closing of $75 Million Public Offering of Common Stock
2021-11-04 02:54 ET
ANI Pharmaceuticals, Inc. Announces Pricing of $75 Million Public Offering of Common Stock
2021-11-03 20:03 ET
ANI Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
2021-11-01 10:45 ET
ANI Pharmaceuticals Reports Third Quarter 2021 Results
2021-11-01 10:30 ET
ANI Pharmaceuticals Announces FDA Approval of Purified Cortrophin™ Gel for Multiple Indications Including Multiple Sclerosis, Rheumatoid Arthritis and Nephrotic Syndrome
2021-10-29 20:30 ET
ANI Pharmaceuticals to Discuss Third Quarter 2021 Financial Results on November 1, 2021
2021-09-20 20:30 ET
ANI Pharmaceuticals to Present at Cantor Virtual Global Healthcare Conference 2021
2021-09-17 10:50 ET
ANI Pharmaceuticals Announces Launch of Nebivolol Tablets
2021-08-31 10:50 ET
ANI Pharmaceuticals Announces FDA Acceptance of Purified Cortrophin® Gel Supplemental New Drug Application for Multiple Indications Including Multiple Sclerosis, Rheumatoid Arthritis, and Nephrotic Syndrome
2021-08-06 11:24 ET
ANI Pharmaceuticals Reports Second Quarter 2021 Results
2021-07-22 20:30 ET
ANI Pharmaceuticals to Discuss Second Quarter 2021 Financial Results on August 6, 2021
2021-07-06 10:50 ET
ANI Pharmaceuticals Announces Refiling of Cortrophin sNDA with FDA
2021-06-15 20:05 ET
ANI Pharmaceuticals to Present at the Raymond James Human Health Innovation Conference 2021
2021-06-01 20:05 ET
ANI Pharmaceuticals Announces Details of 2021 Virtual Annual Meeting of Stockholders
2021-05-27 20:30 ET
ANI Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference 2021
2021-05-07 10:50 ET
ANI Pharmaceuticals Reports First Quarter 2021 Results
2021-04-26 20:30 ET
ANI Pharmaceuticals to Discuss First Quarter 2021 Financial Results on May 7, 2021
2021-04-06 10:50 ET
ANI Pharmaceuticals Expands Branded Products Portfolio Through Acquisition of Sandoz Inc. NDAs
2021-03-09 11:50 ET
ANI Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results; Company Positioned for Sustainable Future Growth
2021-03-09 11:45 ET
ANI Pharmaceuticals to Acquire Novitium Pharma, Strengthening R&D Engine and Expanding Generics and CDMO Business
2021-02-19 21:30 ET
ANI Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-02-17 11:50 ET
ANI Pharmaceuticals Strengthens Leadership Team to Accelerate Future Growth
2021-02-16 21:30 ET
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2020 Financial Results on March 9, 2021
2021-02-01 11:50 ET
ANI Pharmaceuticals Announces Launch of Prazosin Hydrochloride (“HCl”) Capsules
2020-12-17 11:50 ET
ANI Pharmaceuticals Announces Approval and Launch of Aminocaproic Acid Tablets
2020-11-05 11:50 ET
ANI Pharmaceuticals Reports Third Quarter 2020 Results
2020-10-29 10:50 ET
ANI Pharmaceuticals Schedules Conference Call to Discuss Third Quarter 2020 Financial Results
2020-09-10 23:00 ET
ANI Pharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2020-08-06 10:50 ET
ANI Pharmaceuticals Reports Second Quarter 2020 Results
2020-08-06 10:45 ET
ANI Pharmaceuticals Appoints Experienced Pharmaceutical Executives, Jeanne Thoma and Antonio “Tony” Pera to Board of Directors
2020-08-03 10:50 ET
ANI Pharmaceuticals Names Nikhil Lalwani as President and Chief Executive Officer
2020-07-30 10:50 ET
ANI Pharmaceuticals Schedules Conference Call to Discuss Second Quarter 2020 Financial Results
2020-07-06 12:30 ET
ANI Pharmaceuticals Announces Acquisition of Fluconazole Tablets
2020-06-30 12:30 ET
ANI Pharmaceuticals Announces Launch of Mexiletine Hydrochloride Capsules
2020-06-01 12:30 ET
ANI Pharmaceuticals Provides Update on Recent Regulatory Filing
2020-05-07 12:30 ET
ANI Pharmaceuticals Reports First Quarter 2020 Results and Appoints Interim CEO
2020-04-30 12:30 ET
ANI Pharmaceuticals Schedules Conference Call to Discuss First Quarter 2020 Financial Results
2020-04-29 12:30 ET
ANI Receives Refusal to File Letter from FDA for Cortrophin® Gel
2020-04-14 12:30 ET
ANI Announces Upcoming Departure of CEO
2020-04-13 12:30 ET
ANI Announces FDA Acceptance of Supplemental Filing for Cortrophin® Gel 80 U/mL
2020-04-02 12:30 ET
ANI Pharmaceuticals Announces Launch of Omega-3-Acid Ethyl Esters Capsules USP
2020-03-26 12:30 ET
ANI Announces Launch of Polyethylene Glycol 3350, 17g/Packet
2020-03-24 12:30 ET
ANI Pharmaceuticals Announces the Filing of a Prior Approval Supplement for Purified Cortrophin® Gel 80 U/mL
2020-03-02 13:30 ET
ANI Pharmaceuticals Announces FDA Approval of Memantine Hydrochloride Extended-Release Capsules
2020-02-27 13:30 ET
ANI Pharmaceuticals Reports Full Year and Fourth Quarter 2019 Results, Provides 2020 Guidance and Remains on Track to Submit Cortrophin® Gel sNDA to FDA in March 2020
2020-02-20 13:30 ET
ANI Pharmaceuticals Schedules Conference Call to Discuss Fourth Quarter and Year-to-Date 2019 Financial Results
2020-02-12 13:30 ET
ANI Announces Launch of Sulfamethoxazole and Trimethoprim Oral Suspension USP 200 mg/40 mg per 5 mL
2020-01-24 13:30 ET
ANI Announces Launch of Tolterodine Extended-Release Capsules
2020-01-16 13:30 ET
ANI Pharmaceuticals Announces FDA Approval of Potassium Citrate Extended-Release Tablets USP
2020-01-14 13:30 ET
ANI Announces Launch of Paliperidone Extended-Release Tablets
2020-01-14 13:30 ET
ANI Announces Launch of Paliperidone Extended-Release Tablets
2020-01-09 13:30 ET
ANI Pharmaceuticals Announces Acquisition of Commercial and Pipeline Generic Products from Amerigen Pharmaceuticals, Ltd.
2019-11-26 13:30 ET
ANI Pharmaceuticals to Present at Evercore ISI 2nd Annual HealthCONx Conference
2019-11-06 13:30 ET
ANI Pharmaceuticals Reports Third Quarter Results
2019-10-31 12:30 ET
ANI Announces Plans to Launch Bretylium Tosylate Injection, USP 500mg/10ml (50mg/ml) for Ventricular Arrhythmias
2019-10-30 12:30 ET
ANI Pharmaceuticals Schedules Conference Call to Discuss Third Quarter and Year-to-Date 2019 Financial Results
2019-10-29 12:30 ET
ANI Pharmaceuticals announces the launch of ANI Global Source, its contract development and manufacturing business
2019-10-03 12:30 ET
ANI Announces Positive Clinical Results from Cortrophin® Gel Cortisol Response Study
2019-10-02 12:30 ET
ANI Pharmaceuticals Announces Launch of Aspirin and Extended Release Dipyridamole Capsules, 25mg/200mg
2019-09-11 12:30 ET
ANI Pharmaceuticals Announces Launch of Vancomycin Hydrochloride for Oral Solution USP, 250mg/5mL
2019-07-31 12:30 ET
ANI Pharmaceuticals Schedules Conference Call to Discuss Second Quarter and Year-to-Date 2019 Financial Results
2019-06-25 12:30 ET
ANI Pharmaceuticals Announces Launch of Ranitidine Capsules
2019-06-20 14:30 ET
ANI Pharmaceuticals Announces Approval of Vancomycin Hydrochloride for Oral Solution USP, 250mg/5ml
2019-06-18 12:00 ET
ANI Pharmaceuticals Expands Generic Pipeline with Acquisition of Seven Development Stage Drug Products from Coeptis Pharmaceuticals, Inc.
2019-06-12 12:30 ET
ANI Pharmaceuticals to Present at Raymond James Life Sciences and MedTech Conference
2019-05-02 12:30 ET
ANI Pharmaceuticals Schedules Conference Call to Discuss First Quarter 2019 Financial Results
2019-04-15 12:30 ET
ANI Pharmaceuticals Expands Injectable Portfolio with Distribution Agreement for FDA Approved Injectable Product

SEC forms

Show financial reports only

SEC form 8
2024-04-17 00:00 ET
ANI Pharmaceuticals published news for 2024 q1
SEC form 8
2024-04-17 00:00 ET
ANI Pharmaceuticals published news for 2024 q1
SEC form 8
2024-03-12 00:00 ET
ANI Pharmaceuticals published news for 2023 q4
SEC form 8
2024-03-12 00:00 ET
ANI Pharmaceuticals published news for 2023 q4
SEC form 10
2024-02-29 07:22 ET
ANI Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-29 06:58 ET
ANI Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-29 06:58 ET
ANI Pharmaceuticals reported for 2023 q4
SEC form 10
2024-02-29 00:00 ET
ANI Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-08 00:00 ET
ANI Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-08 00:00 ET
ANI Pharmaceuticals published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
ANI Pharmaceuticals published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
ANI Pharmaceuticals published news for 2023 q4
SEC form 8
2023-11-15 00:00 ET
ANI Pharmaceuticals published news for 2023 q3
SEC form 10
2023-11-08 07:01 ET
ANI Pharmaceuticals reported for 2023 q3
SEC form 8
2023-11-08 06:57 ET
ANI Pharmaceuticals published news for 2023 q3
SEC form 8
2023-09-25 00:00 ET
ANI Pharmaceuticals published news for 2023 q2
SEC form 8
2023-09-12 00:00 ET
ANI Pharmaceuticals published news for 2023 q2
SEC form 8
2023-09-07 00:00 ET
ANI Pharmaceuticals published news for 2023 q2
SEC form 8
2023-08-30 00:00 ET
ANI Pharmaceuticals published news for 2023 q2
SEC form 10
2023-08-09 07:00 ET
ANI Pharmaceuticals reported for 2023 q2
SEC form 6
2023-08-09 06:56 ET
ANI Pharmaceuticals published news for 2023 q2
SEC form 8
2023-08-09 00:00 ET
ANI Pharmaceuticals published news for 2023 q2
SEC form 10
2023-08-09 00:00 ET
ANI Pharmaceuticals published news for 2023 q2
SEC form 8
2023-06-09 00:00 ET
ANI Pharmaceuticals published news for 2023 q1
SEC form 6
2023-06-08 20:00 ET
ANI Pharmaceuticals published news for 2023 q1
SEC form 10
2023-05-08 00:00 ET
ANI Pharmaceuticals published news for 2023 q1
SEC form 8
2023-05-08 00:00 ET
ANI Pharmaceuticals published news for 2023 q1
SEC form 8
2023-03-09 00:00 ET
ANI Pharmaceuticals reported for 2022 q4
SEC form 10
2023-03-09 00:00 ET
ANI Pharmaceuticals reported for 2022 q4
SEC form 8
2022-11-09 00:00 ET
ANI Pharmaceuticals reported for 2022 q3
SEC form 8
2022-11-09 00:00 ET
ANI Pharmaceuticals published news for 2022 q3
SEC form 10
2022-11-09 00:00 ET
ANI Pharmaceuticals reported for 2022 q3
SEC form 8
2022-08-08 00:00 ET
ANI Pharmaceuticals reported for 2022 q2
SEC form 10
2022-08-08 00:00 ET
ANI Pharmaceuticals reported for 2022 q2
SEC form 10
2022-05-10 00:00 ET
ANI Pharmaceuticals reported for 2022 q1
SEC form 8
2022-05-10 00:00 ET
ANI Pharmaceuticals reported for 2022 q1
SEC form 8
2022-03-15 00:00 ET
ANI Pharmaceuticals published news for 2021 q4
SEC form 10
2022-03-15 00:00 ET
ANI Pharmaceuticals published news for 2021 q4
SEC form 8
2021-11-01 00:00 ET
ANI Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-01 00:00 ET
ANI Pharmaceuticals published news for 2021 q3
SEC form 8
2021-08-06 00:00 ET
ANI Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-06 00:00 ET
ANI Pharmaceuticals published news for 2021 q2
SEC form 8
2021-05-07 00:00 ET
ANI Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-07 00:00 ET
ANI Pharmaceuticals published news for 2021 q1